429 related articles for article (PubMed ID: 17239709)
1. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Hanefeld M; Marx N; Pfützner A; Baurecht W; Lübben G; Karagiannis E; Stier U; Forst T
J Am Coll Cardiol; 2007 Jan; 49(3):290-7. PubMed ID: 17239709
[TBL] [Abstract][Full Text] [Related]
2. Effects of pioglitazone versus simvastatin on biomarkers of inflammation in patients on high cardiovascular risk.
Hanefeld M; Schaper F; Appelt D; Fuchs W
Horm Metab Res; 2011 Dec; 43(13):980-3. PubMed ID: 22068809
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
Campia U; Matuskey LA; Panza JA
Circulation; 2006 Feb; 113(6):867-75. PubMed ID: 16461819
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
5. Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
Hernandez TL; Capell WH; Wolfe P; Gerard LA; Eckel RH
Am J Cardiol; 2006 Dec; 98(12):1656-9. PubMed ID: 17145229
[TBL] [Abstract][Full Text] [Related]
6. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.
Raji A; Gerhard-Herman MD; Williams JS; O'connor ME; Simonson DC
Diabet Med; 2006 May; 23(5):537-43. PubMed ID: 16681563
[TBL] [Abstract][Full Text] [Related]
8. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure.
Madsen T; Schmidt EB; Christensen JH
J Ren Nutr; 2007 Jul; 17(4):258-63. PubMed ID: 17586424
[TBL] [Abstract][Full Text] [Related]
9. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
Yamada K; Fujimoto S; Tokura T; Fukudome K; Ochiai H; Komatsu H; Sato Y; Hara S; Eto T
Ren Fail; 2005; 27(4):361-5. PubMed ID: 16060120
[TBL] [Abstract][Full Text] [Related]
10. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease.
Dummer CD; Thome' FS; Zingano B; Lindoso A; Veronese FV
J Nephrol; 2008; 21(6):900-8. PubMed ID: 19034875
[TBL] [Abstract][Full Text] [Related]
11. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
Chen YG; Xu F; Zhang Y; Ji QS; Sun Y; Lü RJ; Li RJ
Chin Med J (Engl); 2006 Jan; 119(1):32-6. PubMed ID: 16454979
[TBL] [Abstract][Full Text] [Related]
12. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein.
Guldiken S; Demir M; Arikan E; Turgut B; Azcan S; Gerenli M; Tugrul A
Thromb Res; 2007; 119(1):79-84. PubMed ID: 16476470
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Leonhardt W; Pfützner A; Müller J; Pietzsch J; Forst T; Karagiannis E; Lübben G; Hanefeld M
Atherosclerosis; 2008 Nov; 201(1):155-62. PubMed ID: 18374336
[TBL] [Abstract][Full Text] [Related]
14. Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies.
Yip HK; Sun CK; Chang LT; Wu CJ; Chua S; Fu M
Int J Cardiol; 2007 Oct; 121(3):253-60. PubMed ID: 17196684
[TBL] [Abstract][Full Text] [Related]
15. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
Mora S; Rifai N; Buring JE; Ridker PM
Circulation; 2006 Aug; 114(5):381-7. PubMed ID: 16864722
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
[TBL] [Abstract][Full Text] [Related]
17. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
18. High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome.
Aso Y; Wakabayashi S; Nakano T; Yamamoto R; Takebayashi K; Inukai T
Metabolism; 2006 Aug; 55(8):1014-21. PubMed ID: 16839835
[TBL] [Abstract][Full Text] [Related]
19. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.
Kar P; Laight D; Rooprai HK; Shaw KM; Cummings M
Diabet Med; 2009 May; 26(5):526-31. PubMed ID: 19646193
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.
Kim SH; Chung WY; Zo JH; Kim MA; Chang HJ; Cho YS; Youn TJ; Chae IH; Choi DJ; Gwak JJ; Lee HY; Park JS; Kang HJ; Kim YJ; Kim HS
Clin Ther; 2009 May; 31(5):988-98. PubMed ID: 19539099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
